3-phthalimido-4-chloroindazole | 88805-82-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 3-phthalimido-4-chloroindazole
• 英文别名: 2-(4-chloro-1H-indazol-3-yl)isoindoline-1,3-dione；2-(4-chloro-1H-indazol-3-yl)isoindole-1,3-dione
• CAS: 88805-82-7
• 化学式: C₁₅H₈ClN₃O₂
• 分子量: 297.7
• InChiKey: QHZITZAZGLSGEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-phthalimido-4-chloroindazole 以 N,N-二甲基甲酰胺 为溶剂， 以59%的产率得到1-(3-diethylaminopropyl)-3-phthalimido-4-chloroindazole
  参考文献：
  名称：

  Aminoindazole derivatives

  摘要：

  式(I)的化合物：其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##基团，其中Y是n-C.sub.1-6烷基烯基或具有C.sub.1-6烷基基团取代物的n-C.sub.1-6烷基烯基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基基团，以及##STR3##在##STR4##基团中的基团可能形成从吗啡啉，吡咯啉，哌啶，环己哌啶和哌嗪基团中选择的饱和杂环环；除了吗啡啉基团之外的饱和杂环环可能具有至少一个C.sub.1-4烷基基团，羟基基团或卤原子作为取代物；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基基团或甲氧基基团；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR5##基团是吗啡啉基团；当Z.sub.1是氯原子，羟基，碘原子，甲基基团或甲氧基基团时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基基团，甲氧基基团或氨基时，Z.sub.1在5-位；当Z.sub.1是碘原子时，Z.sub.1在5-位或7-位；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5-位和7-位；以及其生理上可接受的酸盐，这些化合物具有药用价值，例如：用于治疗炎症。

  公开号：

  US04533731A1
• 作为产物：
  描述：

  4-氯-1H-吲唑-3-胺 、 邻苯二甲酸亚胺 生成 3-phthalimido-4-chloroindazole
  参考文献：
  名称：

  IBUKI, TADAYUKI

  摘要：

  DOI：

文献信息

• Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040254177A1

  公开（公告）日：2004-12-16

  Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明揭示了3-氨基吲唑衍生物或其药学上可接受的盐，以及包含它们的制药组合物。这些化合物或组合物在治疗由蛋白激酶活性改变引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• Indazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04751302A1

  公开（公告）日：1988-06-14

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR4## in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof.

  化合物的公式（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，且##STR3##可以形成从吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基中选出的饱和杂环环，除吗啡啶基外的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR4##是吗啡啶基；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5位或7位；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5位和7位；以及其生理上可接受的酸加成盐。
• IBUKI, TADAYUKI;SUGIHARA, TAISUKE;KAWAKUBO, HIROMU;SONE, TAKANORI
  作者：IBUKI, TADAYUKI、SUGIHARA, TAISUKE、KAWAKUBO, HIROMU、SONE, TAKANORI

  DOI：——

  日期：——
• AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1432416A1

  公开（公告）日：2004-06-30
• US4533731A
  申请人：——

  公开号：US4533731A

  公开（公告）日：1985-08-06